Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Anetta Marcinek, MSc, Bettina Brauchle, MSc, Dragica Udiljak, Roman Kischel, MD, Peter Kufer, MD, Karsten Spiekermann, MD, Michael von Bergwelt, MD, Felix S. Lichtenegger, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2018-99-116297

Published: 2018

Journal Articles

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Bettina Lindl, Christina Krupka, PhD, Tara Chapman-Arvedson, Roman Kischel, MD, Peter Kufer, MD, Sascha Haubner, MD, Felix S. Lichtenegger, MD, Thomas Koehnke, MD, Klaus H. Metzeler, MD, Nikola Konstandin, PhD, Karsten Spiekermann, Wolfgang Hiddemann, MD PhD, Marion Subklewe, MD

Blood (2017) 130 (Supplement 1): 2656.

https://doi.org/10.1182/blood.V130.Suppl_1.2656.2656

Published: 2017

Journal Articles

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Matthias Klinger, PhD, Gerhard Zugmaier, MD, Virginie Naegele, PhD, Mariele Goebeler, MD, Christian Brandl, MS, Ralf C Bargou, MD, Peter Kufer, MD

Blood (2016) 128 (22): 1589.

https://doi.org/10.1182/blood.V128.22.1589.1589

Published: 2016

Journal Articles

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Christina Krupka, Bettina Lindl, Thomas Köhnke, MD, Julia Platzer, Lavinia Pachzelt, Felix S Lichtenegger, MD, Torben Altmann, Peter Kufer, MD, Roman Kischel, MD, Wolfgang Hiddemann, MD, PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 3940.

https://doi.org/10.1182/blood.V128.22.3940.3940

Published: 2016

Journal Articles

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Christina Krupka, Thomas Köhnke, MD, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3677.

https://doi.org/10.1182/blood.V126.23.3677.3677

Published: 2015

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Jan Bögeholz, Thomas Köhnke, Felix S. Lichtenegger, Stephanie Schneider, Klaus H. Metzeler, Michael Fiegl, Karsten Spiekermann, Patrick A. Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe

Blood (2014) 123 (3): 356–365.

https://doi.org/10.1182/blood-2013-08-523548

Published: 2014

Includes: Supplemental data

Journal Articles

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Jan Boegeholz, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Stephanie Schneider, PhD, Klaus H. Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, Marion Subklewe, MD

Blood (2013) 122 (21): 239.

https://doi.org/10.1182/blood.V122.21.239.239

Published: 2013

Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blood (2012) 120 (26): 5185–5187.

https://doi.org/10.1182/blood-2012-07-441030

Published: 2012

Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer

Blood (2012) 119 (26): 6226–6233.

https://doi.org/10.1182/blood-2012-01-400515

Published: 2012

Includes: Supplemental data

Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Blood (2011) 118 (21): 1637.

https://doi.org/10.1182/blood.V118.21.1637.1637

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Autologous T Cells From AML Patients Can Be Effectively Recruited for In-Vitro Lysis of Blasts by a Novel CD33/CD3-Bispecific BiTE Antibody

Michael Aigner, PhD, Julian Feulner, Roman Kischel, MD, Peter Kufer, MD, Patrick A Baeuerle, PhD, Andreas Mackensen, MD, Stefan W. Krause, MD

Blood (2010) 116 (21): 14.

https://doi.org/10.1182/blood.V116.21.14.14

Published: 2010

Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 2880.

https://doi.org/10.1182/blood.V116.21.2880.2880

Published: 2010

Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou

Blood (2009) 114 (22): 2723.

https://doi.org/10.1182/blood.V114.22.2723.2723

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Gerhard Zugmaier, Dirk Nagorsen, Matthias Klinger, Ralf C Bargou, Mariele Goebeler, Andreas Viardot, Patrick A Baeuerle, Peter Kufer

Blood (2009) 114 (22): 4793.

https://doi.org/10.1182/blood.V114.22.4793.4793

Published: 2009

Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou

Blood (2009) 114 (22): 4798.

https://doi.org/10.1182/blood.V114.22.4798.4798

Published: 2009

Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD

Blood (2008) 112 (11): 1926.

https://doi.org/10.1182/blood.V112.11.1926.1926

Published: 2008

NARROW

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Autologous T Cells From AML Patients Can Be Effectively Recruited for In-Vitro Lysis of Blasts by a Novel CD33/CD3-Bispecific BiTE Antibody

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only